Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
05 avr. 2021 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas
03 févr. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
$135 Billion Immuno-Oncology Markets, 2024
07 janv. 2021 08h13 HE
|
Research and Markets
Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Market, by Type (mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)), by Application (Lung,...
INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR LACUTAMAB IN SÉZARY SYNDROME
13 nov. 2020 01h00 HE
|
INNATE PHARMA
Marseille, France, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the European Medicines...
INNATE PHARMA REÇOIT LE STATUT « PRIME » DE L’AGENCE EUROPÉENNE DU MÉDICAMENT POUR LACUTAMAB DANS LE SYNDROME DE SÉZARY
13 nov. 2020 01h00 HE
|
INNATE PHARMA
Marseille, France, 13 nov. 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé que l’Agence Européenne...
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
01 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...
Global Follicular Lymphoma Market Insights, Epidemiology and Forecast 2017-2019 & 2020-2030
22 sept. 2020 04h48 HE
|
Research and Markets
Dublin, Sept. 22, 2020 (GLOBE NEWSWIRE) -- The "Follicular Lymphoma - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. Follicular...
Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform
13 juin 2019 06h55 HE
|
Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., June 13, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it has...
斯丹赛生物技术有限公司 Innovative Cellular Therapeutics 宣佈圓滿完成與 FDA 的臨床試驗審請前（Pre-IND）會議
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
中國上海和馬里蘭州羅克維爾, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司 (Innovative Cellu lar Therapeutics, ICT）是一間生物技術公司，主力開發治療癌症的細胞免疫療法。該公司在今天宣布與美國食品和藥物管理局（FDA）的臨床試驗審查前會議﹙研究性新藥﹚已圓滿結束。在會議上，FDA 就 ICT...
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
SHANGHAI, China and ROCKVILLE, Md., April 09, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of...